Q1 2025 Earnings Call Transcript May 8, 2025 Royalty Pharma plc beats earnings expectations. Reported EPS is $1.06, ...

Biogen is aiming to expand across the West Coast and is planning to open a hub in South San Francisco. Good news for Bay Area ...

As biopharma companies continue to roll out their first-quarter  earnings, Trump administration tariffs remain at the top of investors’ minds. While executives offer their various strategies to ...

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have ...

Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies LOS ANGELES, May 08, 2025 ...

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

Shares of Biogen Inc. BIIB slipped 4.09% to $116.82 Tuesday, on what proved to be an all-around grim trading session for the ...

In April 2025, Pfizer organized a study is to learn about the effects, safety and how PF-06823859 is processed in adults with ...

The acquisition of Regulus Therapeutics, a California-based biotechnology company focused on microRNA therapies, by Novartis ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.